Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure (http://www.onlinejcf.com/), published by Elsevier.

The authors previously demonstrated that venous endothelium is a key regulator of central blood volume, organ perfusion and hemostasis in heart failure (HF). The present study demonstrates that in venous endothelium, inflammatory/oxidative and hemostatic programs were significantly activated in HF dogs compared to normal dogs. In normal dogs, fluid loading significantly activated these same programs to levels that approached those seen in dogs with HF.

These findings suggest that biomechanical stress (i.e. vascular stretch) may be an important mediator of these endothelial responses, and highlight the importance of preventing congestion. Further investigation is needed to clarify whether the venous endothelial phenotype in unique individuals may ultimately allow us to track the vascular impact of subsequent environmental (i.e. biomechanical and biochemical) stressors, as well as the potential response to therapeutic interventions.

“This important study is consistent with a growing literature, indicating that congestion itself may mediate many of the physiological abnormalities in heart failure, such as vascular dysfunction, inflammation, renal dysfunction and hypercoagulability,” commented Barry M. Massie, M.D., Editor-in-Chief of the Journal of Cardiac Failure.

###

Notes to Editors:

The study, “Activation of Endothelial Cells in Conduit Veins of Dogs with Heart Failure and Veins of Normal Dogs Following Vascular Stretch by Acute Volume Loading,” authored by Paolo C. Colombo, Sharad Rastogi, Duygu Onat, Valerio Zacà, Ramesh C. Gupta, Ulrich P. Jorde, and Hani C. Sabbah (DOI: 10.1016/j.cardfail.2008.12.006) was supported by a research grant from the National Heart, Lung and Blood Institute. It appears in the Journal of Cardiac Failure, Volume 15, Issue 5 (June 2009) published by Elsevier.com

About Journal of Cardiac Failure

Journal of Cardiac Failure (http://www.onlinejcf.com/) publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure—pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment. Journal of Cardiac Failure is the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. It has an Impact Factor of 3.067 (the highest among journals with a heart failure focus and 19th among all cardiovascular journals) and an Immediacy Factor of 1.306, the 7th among all cardiovascular journals.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,700 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). Additional information on HFSA can be found at http://www.hfsa.org.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact: Maureen Hunter
.(JavaScript must be enabled to view this email address)
215-239-3671
Elsevier